Providing personalized prognostic information for adult leukemia survivors.

Published

Journal Article

Prediction of subsequent leukemia-free survival (LFS) and chronic graft-versus-host disease (GVHD) in adults with acute leukemia who survived at least 1 year after allogeneic hematopoietic cell transplantation is difficult. We analyzed 3339 patients with acute myeloid leukemia and 1434 patients with acute lymphoblastic leukemia who received myeloablative conditioning and related or unrelated stem cells from 1990 to 2005. Most clinical factors predictive of LFS in 1-year survivors were no longer significant after 2 or more years. For acute myeloid leukemia, only disease status (beyond first complete remission) remained a significant adverse risk factor for LFS 2 or more years after transplantation. For lymphoblastic leukemia, only extensive chronic GVHD remained a significant adverse predictor of LFS in the second and subsequent years. For patients surviving for 1 year without disease relapse or extensive chronic GVHD, the risk of developing extensive chronic GVHD in the next year was 4% if no risk factors were present and higher if noncyclosporine-based GVHD prophylaxis, an HLA-mismatched donor, or peripheral blood stem cells were used. Estimates for subsequent LFS and extensive chronic GVHD can be derived for individual patients or populations using an online calculator (http://www.cibmtr.org/LeukemiaCalculators). This prognostic information is more relevant for survivors than estimates provided before transplantation.

Full Text

Duke Authors

Cited Authors

  • Lee, SJ; Storer, B; Wang, H; Lazarus, HM; Waller, EK; Isola, LM; Klumpp, TR; Umejiego, JBC; Savani, BN; Loren, AW; Cairo, MS; Camitta, BM; Cutler, CS; George, B; Jean Khoury, H; Marks, DI; Rizzieri, DA; Copelan, EA; Gupta, V; Liesveld, JL; Litzow, MR; Miller, AM; Schouten, HC; Gale, RP; Cahn, J-Y; Weisdorf, DJ

Published Date

  • November 2013

Published In

Volume / Issue

  • 19 / 11

Start / End Page

  • 1600 - 1607

PubMed ID

  • 24018394

Pubmed Central ID

  • 24018394

Electronic International Standard Serial Number (EISSN)

  • 1523-6536

Digital Object Identifier (DOI)

  • 10.1016/j.bbmt.2013.08.013

Language

  • eng

Conference Location

  • United States